EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, AVXL: Anavex Lf SC

22 Oct 25 15:59
LAST:

9.330

CHANGE:
 0.00		OPEN:
9.370		HIGH:
10.460		ASK:
4.480		VOLUME:
358.6K
CHG(%):
0.00		PREV:
9.350		LOW:
9.180		BID:
3.860		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Oct 259.3509.5009.1809.350568.6K
21 Oct 259.3509.4809.2609.350516.8K
20 Oct 259.1409.5009.0309.3601.06M
17 Oct 258.9009.2488.8958.980749.3K
16 Oct 259.0009.2808.8909.010987.1K
15 Oct 258.8009.0808.6659.0301.06M
14 Oct 258.5809.0388.0598.7951.11M
13 Oct 259.2909.2908.3408.6202.32M
10 Oct 259.4409.5259.0009.2703.57M
09 Oct 259.8309.9509.5109.5201.39M

COMPANY PROFILE

Name:Anavex Lf SC
About:Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Its lead drug candidate, ANAVEX 2-73 (blarcamesine), which has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against the Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.
Sector:Healthcare
Industry:Biotechnology
Address:630 5th Avenue, New York, NY, United States, 10111
Website:https://www.anavex.com
CUSIP:032797102
CIK:0001314052
ISIN:US0327973006
FIGI:BBG000C9K8K4
LEI:549300K1I5L8COCQ8W36

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:9.211.3%
MA10:9.132.2%
MA20:9.171.8%
MA50:9.280.6%
MA100:9.714.1%
MA200:9.300.4%
STO9:80.66 
STO14:41.48
RSI14:53.14
WPR14:-45.52
MTM14:-0.61
ROC14:-0.06 
ATR:0.56 
Week High:9.501.8%
Week Low:8.677.7%
Month High:10.3811.3%
Month Low:8.060.4%
Year High:14.4454.8%
Year Low:5.2278.7%
Volatility:63.14 

RECENT SPLITS

Date Ratio
07 Oct 20151-4